ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Robert C. Robbins
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Feeley, B. T.
Right arrow Articles by Robbins, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Feeley, B. T.
Right arrow Articles by Robbins, R. C.

Ann Thorac Surg 1999;68:119-124
© 1999 The Society of Thoracic Surgeons

Original Articles

Pressure delivery of AS-ICAM-1 ODN with LFA-1 mAb reduces reperfusion injury in cardiac allografts

Brian T. Feeley, BSa, Aric K. Park, BSa, Sophoclis Alexopoulos, BSa, E. Grant Hoyta, Michael P. Ennen, BSa, Robert S. Poston, Jr, MDa, Robert C. Robbins, MDa

a Department of Cardiothoracic Surgery, Stanford University Medical Center, Stanford, California, USA

Address reprint requests to Dr Robbins, Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, CA 94305-5407
e-mail: robbins{at}leland.stanford.edu

Background. The goal of this study is to determine the effects of ex vivo hyperbaric pressure administration of AS-ICAM-1 ODN and systemic anti-LFA-1 mAb treatment on reperfusion injury in the rat cardiac allograft model.

Methods. A PVG to ACI functional heterotopic rat heart model was used. Donor hearts were treated with either saline or AS-ICAM-1 ODN and 5 atm of hyperbaric pressure for 45 minutes. Anti-LFA-1 mAb was administered systemically prior to reperfusion of the allograft. Allografts were procured 24 hours after transplantation for assessment of reperfusion injury or 72 hours to determine ICAM-1 protein expression.

Results. Ex vivo administration of AS-ICAM-1 ODN led to decreases in percentage wet weight (77.1 ± 0.83% vs 78.7 ± 1.0%, p< 0.05), myeloperoxidase activity (3.14 ± 0.72 vs 4.07 ± 0.59, p < 0.05), contraction band necrosis (6.4 ± 6.47% vs 21.1 ± 7.43%, p< 0.01), and ICAM-1 protein expression determined by immunohistochemistry compared to saline controls. Treatment with anti-LFA-1 mAb resulted in decreases in wet weight ratio (76.7 ± 0.63%,p < 0.05 vs saline), myeloperoxidase activity (3.58 ± 0.39,p < 0.05 vs saline) and contraction band necrosis (11.8 ± 3.56%, p < 0.05 vs saline). Combination of pressure administration of AS-ICAM-1 ODN and anti-LFA-1 mAb decreased wet weight ratios (77.1 ± 0.93%, p < 0.05 vs saline), myeloperoxidase activity (2.88 ± 0.44, p < 0.01 vs saline), and contraction band necrosis (6.75 ± 5.67%,p < 0.05 vs saline).

Conclusions. Ex vivo pressure mediated delivery of AS-ICAM-1 ODN decreases ICAM-1 protein expression, reduces reperfusion injury in rodent cardiac allografts, and is more effective than anti-LFA-1 mAb treatment alone.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1999 by The Society of Thoracic Surgeons.